摘要
目的 :观察缬沙坦联合美托洛尔治疗慢性充血性心力衰竭 (CHF)的临床疗效。方法 :96例CHF患者随机分为 :A组 (n =4 6 )给予洋地黄及利尿剂等常规治疗 ,B组 (n =5 0 )在常规治疗的基础上口服缬沙坦 (4 0～ 16 0mg·d-1)和美托洛尔 (12 .5～ 10 0mg·d-1) ,疗程均为 6个月。结果 :治疗后B组患者心功能改善、血压下降、心率减慢、心胸比缩小 ,左室舒张末期内径 (LVDd)及左房内径 (LAd)均明显减小 ,左室射血分数 (LVEF)增加 (P <0 .0 5 ) ,明显优于A组 ;且副作用少、患者耐受性好。结论 :缬沙坦联合美托洛尔治疗CHF疗效肯定、副作用少 ,值得临床推广。
Objective:To evaluate the therapeutic efficacy of valsartan accompanied with metoprolol in the patients with congestive heart failure(CHF).Methods: 96 patients with CHF were randomly divided into group A ( n =46) who had taken conventional treatment of digitalis and diuretics and group B ( n =50) who were given valsartan (40 to 160 mg·d -1 ) and metoprolol (12.5 to 100 mg·d -1 ) on the conventional therapy.The therapeutic period was 6 months. Results: After treatment,cardiac function (NYHA) improved; blood pressure,heart rate,cardiothoracic ratio,left ventricular diastolic ending diameter (LVDd) and left aurial diameter (LAd) all decreased; left ventricular ejectional fraction (LVEF) increased significantly( P <0.05 ) in group B comparing with those in group A. There were few side effects and patients' tolerance was perfect in Group B.Conclusion:The therapeutic efficacy of valsartan accompanied with metoprolol in the patients with congestive heart failure(CHF) is satisfactory. There are few side effects.
出处
《西北国防医学杂志》
CAS
2004年第4期281-283,共3页
Medical Journal of National Defending Forces in Northwest China
